Recent Updates
Recently added Catalysts
ZVRA Positive Sentiment

Zevra Reports Second Quarter 2026 Financial Results and Corporate Update

Wednesday, August 5, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Zevra reported a net revenue of $39.7 million for Q2 2026, marking a 53% increase from the previous year. The revenue growth was primarily driven by $30.2 million from MIPLYFFA. The company also highlighted a robust cash position of $260.2 million. A conference call is scheduled for August 5, 2026, to discuss these results.

Market Sentiment Analysis

POSITIVE FACTORS

  • Significant revenue growth of 53% compared to Q2 2025.
  • Strong cash position of $260.2 million.
  • Successful performance driven by MIPLYFFA.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+71%
120-day peak, hindsight
Typical move
10.7%
average across 6 past catalysts
Lead asset
KP415
Phase 3 · ADHD

Full Press Release Details

$39.7 million net revenue for Q2 2026, driven by $30.2 million in revenue from MIPLYFFA 53% increase in total net revenue over Q2 2025 Operational execution fueled strong cash position of $260.2 million Company to host conference call and webcast TODAY, August 5, 2026, at 4:30 p.m. ET BOSTON, Aug.

Frequently Asked Questions

What was Zevra's net revenue for Q2 2026?

Zevra reported a net revenue of $39.7 million for Q2 2026.

How much did MIPLYFFA contribute to revenue?

MIPLYFFA contributed $30.2 million to Zevra's revenue.

What was the revenue growth compared to Q2 2025?

Zevra experienced a 53% increase in total net revenue over Q2 2025.

What is Zevra's cash position as of Q2 2026?

Zevra's cash position stands at $260.2 million.

When will Zevra host a conference call?

Zevra will host a conference call on August 5, 2026, at 4:30 p.m. ET.

ShareAdd on Google
Tags: ZVRA Viatris Investor Conferences Healthcare MIPLYFFA financial results revenue growth corporate update
Last updated: Aug 5, 2026

Biotech snapshot

Cash runway
$260M liquidity · $0M/mo burn
Low dilution risk
Lead asset
KP415Phase 3
ADHD →

Catalyst track record

+71%
best trade around ZVRA's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ZVRA.

See every catalyst's timing & PoA →